IDEXX Laboratories Inc (IDXX) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$464.59 after a previous close of US$465.82. During the day the price has varied from a low of USD464.59 to a high of USD484.06. The latest price was USD482.6 (25 minute delay). IDEXX Laboratories is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
IDEXX Laboratories's shares were split on a 2:1 basis on 16 June 2015. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
| Open | US$464.59 |
|---|---|
| High | US$484.06 |
| Low | US$464.59 |
| Close | US$482.6 |
| Previous close | US$465.82 |
| Change | US$16.78 |
| Change % | 3.6022% |
| Volume | 479,335 |
| 52-week range | US$372.5 - US$564.735 |
|---|---|
| 50-day moving average | US$435.5386 |
| 200-day moving average | US$476.9477 |
| Target price | US$515.25 |
| PE ratio | 48.7939 |
| Dividend yield | US$0 (0.73%) |
| Earnings per share (TTM) | US$9.8 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $482.6
| 1 week (2023-11-22) | 0.89% |
|---|---|
| 1 month (2023-11-03) | 12.42% |
| 3 months (2023-09-01) | -5.61% |
| 6 months (2023-06-02) | 2.50% |
| 1 year (2022-12-02) | 10.87% |
|---|---|
| 2 years (2021-12-03) | -17.72% |
| 3 years (2020-12-03) | 4.90% |
| 5 years (2018-12-03) | 133.86% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, IDEXX Laboratories shares trade at around 49x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.2076. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$1.2 billion (£0.0 million).
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as US$372.5 up to US$564.735. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 1.207. This would suggest that IDEXX Laboratories's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
| Revenue TTM | US$3.6 billion |
|---|---|
| Operating margin TTM | 30.07% |
| Gross profit TTM | US$2 billion |
| Return on assets TTM | 23.54% |
| Return on equity TTM | 92.79% |
| Profit margin | 22.93% |
| Book value | 15.619 |
| Market capitalisation | US$39.7 billion |
TTM: trailing 12 months
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.79
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 01/01/2019) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 17.91/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
IDEXX Laboratories Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.79 |
|---|---|
| Total ESG percentile | 54.84 |
| Environmental score | 9.93 |
| Environmental score percentile | 6 |
| Social score | 14.44 |
| Social score percentile | 6 |
| Governance score | 17.91 |
| Governance score percentile | 6 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
